Concepedia
7
Publications
294
Citations
H-Index
2019
Active since
Affiliations
Genmab (Netherlands)(Current)
Amsterdam University Medical Centers
Leiden University Medical Center
Amsterdam UMC Location Vrije Universiteit Amsterdam
Cancer Center Amsterdam
Hilma J. van der Horst is an author at Genmab (Netherlands).
Publications per year
2019–2021
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
Hilma J. van der Horst, A. Vera de Jonge, Ida H. Hiemstra et al. · Blood Cancer Journal · 2021 · 94 citations · Full text
DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies
Simone C. Oostindie, Hilma J. van der Horst, Laurens P. Kil et al. · Blood Cancer Journal · 2020 · 68 citations · Full text
CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering
Simone C. Oostindie, Hilma J. van der Horst, Margaret A. Lindorfer et al. · Haematologica · 2019 · 61 citations · Full text
Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma
Hilma J. van der Horst, Anne T. Gelderloos, Martine E.D. Chamuleau et al. · Blood Advances · 2021 · 22 citations · Full text
Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant
Lisa C. Holthof, Arwen Stikvoort, Hilma J. van der Horst et al. · HemaSphere · 2021 · 22 citations · Full text
Rows per page
1–5 of 7